MedTrace Logo

Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People

NCT05667714 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2900

Last updated 2023-01-12

No results posted yet for this study

Summary

This is a randomized, single-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of SA58 nasal spray in close contact with COVID-19 people.

Conditions

Interventions

DRUG

SA58 Nasal Spray

SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.

DRUG

Placebo

Placebo was provided by Sinovac Life Sciences Co. , Ltd.

Sponsors & Collaborators

  • Beijing Ditan Hospital

    collaborator OTHER

  • Sinovac Life Sciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ronghua Jin · Beijing Ditan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-26
Primary Completion
2022-12-30
Completion
2023-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05667714 on ClinicalTrials.gov